How Do Wegovy, Ozempic and Mounjaro Work?

On social media, the medicines sold as Wegovy, Ozempic and Mounjaro are presented almost entirely as weight loss drugs. Yet Ozempic is approved only to control blood sugar in type 2 diabetes. Among people online who explained why they were taking it, 2% named type 2 diabetes. The remaining 98%, by contrast, took it to lose weight or to treat polycystic ovary syndrome (a hormonal condition).

The brand names now travel further than the medicines inside them. In 2023, United States (US) posts on X named Ozempic 4.5 times as often as Semaglutide, its active ingredient. Mounjaro, meanwhile, appeared in 9% of weight loss posts, ahead of Semaglutide at 6%. Only 7% to 10% of those posts came from people identifying as doctors. On Instagram, the Ozempic name has been used to sell herbal products containing no Semaglutide at all.

About one in ten popular posts on Semaglutide contained errors, often about what Ozempic and Wegovy are approved to treat. Most Instagram and TikTok posts came from women taking the drug who had no medical knowledge. YouTube, where nearly half the posts came from healthcare professionals, proved the most reliable platform.

Yet a professional author offered no guarantee of quality. Among Spanish-language TikTok videos about Semaglutide, 56% came from healthcare professionals. Even so, they averaged 29.8 out of 75 on DISCERN, a tool scoring the quality of health information.

The same shift shows up in prescribing records. In Denmark, 99% of people starting Ozempic in 2018 had type 2 diabetes. By 2022, that share had fallen to 67%, so one in three new users had no diabetes record. The share without diabetes then dropped back to 13% of new users in 2023. Norway recorded a sharp rise in Ozempic dispensed without reimbursement between 2021 and 2022.

Dispensing without reimbursement marks off-label use (use outside the approved purpose). Google searches pointed in the same direction, with Semaglutide and tirzepatide drawing the most off-label weight-loss interest. In the United States, spending on these medicines rose by more than 500% between 2018 and 2023.

Behind the noise sits a simpler structure than the brand names suggest. The confusion has had consequences beyond social media, for supply, for prescribing and for people with diabetes. Doctors posting online described GLP-1 medicines (drugs copying the gut hormone glucagon-like peptide-1) as having revolutionised diabetes treatment. However, they also stressed that these are serious medicines that work best alongside lifestyle and behaviour changes. Scientists, meanwhile, still debate how much the second hormone Mounjaro copies actually adds.

Our earlier explainer on what GLP-1 weight loss drugs are covers the hormone science in depth. Here, the focus narrows to what separates the names. Part of the answer lies inside the body, where one of these medicines reaches places the others cannot. Part lies in paperwork, where official approvals and National Health Service (NHS) rules decide who gets each medicine. And part depends on when Wegovy, Ozempic and Mounjaro leave clinical trials for everyday use.

Wegovy, Ozempic and Mounjaro: Three Names, Two Medicines

Each of these brands contains one of two active ingredients:

• Semaglutide is the active ingredient in Ozempic, Wegovy and two daily tablets.
• Rybelsus is the diabetes tablet, while a higher-dose Wegovy tablet targets weight.
• Tirzepatide powers Mounjaro and, in the US, a second weight loss brand called Zepbound.

In other words, each brand name signals a form, a dose, and a licence (official approval for specific uses). That structure explains how Wegovy, Ozempic and Mounjaro became so tangled in public use. Ozempic and Wegovy are the clearest case: one molecule, two brands and two separate jobs.

Before Wegovy arrived, people seeking Semaglutide for weight loss had few licensed options. In Denmark, Wegovy only became available in December 2022. Until then, people with obesity but no diabetes probably asked doctors to prescribe Ozempic instead. Cost added to the pull. Danish reimbursement covers Ozempic for type 2 diabetes, with minimal co-payment. By contrast, Ozempic for obesity and Wegovy are generally not reimbursed.

Meanwhile, obesity in Denmark is twice as common in socioeconomically disadvantaged groups as among people on high incomes. Patients can therefore be expected to press doctors for a subsidised medicine such as Ozempic. In Germany, statutory health insurance does not pay for Semaglutide without type 2 diabetes, classing it as a lifestyle medicine.

Demand soon outran supply. From 2022, Ozempic faced a global shortage, leaving some people with type 2 diabetes unable to get it. Causes included a surge in prescribing, manufacturing limits, and a spike in off-label use. In Denmark, adults started Ozempic at about 4 per 1,000 a year in 2019 and 2020. That rate then climbed to a peak of 10 per 1,000 in early 2023, before falling sharply. Over the same period, the share of Danish adults using Ozempic rose almost tenfold.

Danish evidence suggests off-label use explains only a small part of the shortage. Off-label prescribing there rose until 2022, then declined in 2023. Most people with type 2 diabetes who started Ozempic in 2023 had a clear medical reason. Between 68% and 83% had poorly controlled blood sugar despite other diabetes medicines. Meanwhile, 29% had established heart or kidney disease.

In addition, updated guidelines made medicines like Semaglutide a preferred choice for people with diabetes and heart or kidney disease. Those groups may include more than a third of everyone with type 2 diabetes. Wegovy’s arrival in Denmark is likely linked to the fall in off-label Ozempic use. Adults started Wegovy at a peak rate of 32 per 1,000 a year in early 2023. During that year, Wegovy reached roughly as many users as Ozempic.

Shortages also reached newer dual-hormone medicines, so supply problems touched Wegovy, Ozempic and Mounjaro alike. In July 2023, a National Patient Safety Alert across the United Kingdom (UK) addressed the shortages. It told doctors to prescribe the medicines only for licensed uses, and not to start new patients. Prescribing shifted quickly afterwards. Prescriptions of liraglutide (an older, daily GLP-1 medicine) fell significantly across the UK.

Semaglutide prescriptions rose sharply instead, suggesting prescribers were switching patients between medicines. Wales had the highest prescribing rates for most of these medicines. A later NHS update replaced the alert, while warning that supply would stay limited until the end of 2024.

Supply problems left Saxenda (liraglutide for weight management) and Wegovy unavailable in some NHS specialist weight services. National instructions to restrict GLP-1 prescribing followed. Those restrictions limited NHS prescriptions and widened inequalities, because private prescriptions may not follow the same instructions. The tablet form also carries a supply cost. Oral Semaglutide’s top diabetes dose is 14 mg a day. That uses far more drug than a weekly 2.4 mg injection. This extra demand is likely adding to global shortages.

People with type 2 diabetes are worried that soaring weight loss demand would strain supply and push up prices. In US online discussions, they also feared losing insurance coverage for medicines they depended on.

How Ozempic and Wegovy Work: The Same Medicine at Different Doses

Semaglutide is approved for type 2 diabetes at one long-term dose and for obesity at a higher one. Wegovy is injected at 2.4 mg a week for weight management. Ozempic, by contrast, tops out at 2 mg a week for blood sugar control. The same pattern runs through the older medicine liraglutide, sold as Victoza for diabetes and Saxenda for obesity.

These medicines were developed to treat high blood sugar. At high doses, however, they cut body weight by amounts large enough to matter for health. Appetite runs on linked brain systems. The hypothalamus, a small brain region, balances energy needs, while the reward system drives the pleasure of eating.

Meanwhile, the frontal lobe applies conscious control over food choices. In obesity, these networks are altered. How Semaglutide copies GLP-1 to calm those signals is set out in our earlier explainer. Of Wegovy, Ozempic and Mounjaro, only the first two share a molecule, so dose and licence alone separate them.

Ozempic

Ozempic was first approved for type 2 diabetes in the US in 2017 and in Europe in 2018. Across diabetes trials, doses up to 1 mg lowered HbA1c (a three-month blood sugar average) by up to 1.8 points. Weight fell too, by up to 6.5 kg. Since 2015, large trials have shown this class reduces heart and kidney complications in people with high-risk diabetes.

Wegovy

Semaglutide was approved for weight loss as Wegovy in 2021 in the US and in 2022 in Germany. That made it the first of Wegovy, Ozempic and Mounjaro to carry a weight management licence. Approval followed studies showing average weight loss of about 12% during Semaglutide treatment. The STEP trials then tested 2.4 mg weekly against a placebo (dummy treatment), alongside lifestyle changes. They ran for 68 to 104 weeks in adolescents and adults without diabetes.

One trial tested both doses directly in people with type 2 diabetes. Across 68 weeks, 1,210 people received 2.4 mg, 1.0 mg or a placebo. Body weight fell by 9.6% on 2.4 mg, against 7.0% on 1.0 mg and 3.4% on placebo. HbA1c, by contrast, fell almost equally on both doses: 1.6 points against 1.5. So the extra Semaglutide mainly bought extra weight loss, while blood sugar control barely moved.

The Tablets

Semaglutide is also made as a daily tablet. Rybelsus, approved for type 2 diabetes in 2020, goes up to 14 mg a day. Current UK packs use a newer tablet, where 9 mg matches the effect of the original 14 mg. On its own, a peptide (a short chain of protein building blocks) like Semaglutide would be destroyed in the stomach. Each tablet therefore contains an absorption enhancer, salcaprozate sodium, which protects the drug and lets it cross the stomach lining.

A higher-dose tablet now exists for weight management. A daily 25 mg tablet produces similar drug levels in the body to a weekly 2.4 mg injection. A 64-week trial then tested the 25 mg tablet in 307 adults without diabetes. Body weight fell by 13.6%, against 2.2% on placebo. Half of those taking it lost at least 15% of their body weight.

An indirect comparison, built from separate trials, put the injection ahead by 0.55 to 1.01 percentage points. That gap sits well below 5%, the minimum the US Food and Drug Administration suggests for clinically relevant weight loss. Waist size, blood pressure, blood sugar and cholesterol showed no clear difference between the two forms. However, the comparison relied on different trials, with 307 participants in one and almost 2,000 in the other.

Novo Nordisk, which makes Semaglutide, funded and designed the tablet trial and ran its analyses. Most participants were women (78.8%) and White (91.5%), and about one in five did not complete treatment. Whether tablets hold weight loss over years, and how they compare directly with injections, remains unknown.

Tablets bring practical trade-offs, too. They avoid needles and may not need refrigeration during delivery, which could widen access where cold storage is scarce. Yet the strict empty-stomach routine could make daily use harder to sustain.

How Mounjaro Works: Copying Two Gut Hormones at Once

Glucose-dependent insulinotropic polypeptide (GIP) was the first incretin hormone identified, more than a decade before GLP-1. Incretins are gut hormones that boost insulin release after a meal. GIP’s original name was gastric inhibitory polypeptide, because it reduces stomach acid. Tests in people then showed it powerfully stimulated insulin, with little effect on the stomach. So researchers renamed it, keeping the same initials.

Specialised K cells in the upper small intestine release GIP when they sense sugar, fat and protein. Because these cells lie near the start of the gut, GIP rises quickly after eating. Levels climb 5 to 15 times above fasting and stay high until the upper gut empties. Natural GIP then lasts 5 to 7 minutes before the enzyme dipeptidyl peptidase-4 breaks it down.

Each hormone works through its own receptor (a docking point on cells). In healthy people, GIP provides most of the insulin boost that follows a meal. When healthy volunteers received a drug blocking the GIP receptor, their bodies handled sugar less well and released less insulin.

Blocking GIP shifted insulin and blood sugar more than blocking GLP-1 did. In type 2 diabetes, however, GIP’s insulin effect is muted. At matched doses, GLP-1 produced a substantially greater insulin response than GIP. Four weeks of near-normal blood sugar improved responses to both hormones, but only from about 10% to 25% of normal. For a long time, GIP lagged behind GLP-1 as a target for treating diabetes and obesity.

Wegovy, Ozempic, and Mounjaro all act on GLP-1 receptors, but only Mounjaro also acts on GIP receptors. Tirzepatide, its active ingredient, is built mainly on GIP’s amino acid sequence, with an attached fatty acid chain. That chain gives it a half-life (time for half a dose to clear) of about five days, allowing weekly injections. Furthermore, it binds the GIP receptor much more strongly than the GLP-1 receptor.

Tirzepatide is the first approved single molecule to switch on more than one hormone receptor. In effect, it pairs two mechanisms inside one molecule, much as some older obesity treatments combined two separate drugs. Its success has revived interest in GIP, and many GIP-targeting drugs are now in development.

GIP’s receptors are spread across the body. They appear in the insulin-making cells of the pancreas and in bone cells. Fat tissue carries them too, although scientists debate whether they are on fat cells themselves. In the brain, they occupy appetite areas, including regions outside the blood-brain barrier (the brain’s protective filter). Those regions are directly exposed to hormones carried in the blood. GIP and GLP-1 receptors share these areas, yet they are rarely found on the same nerve cells.

What GIP adds in people is harder to pin down. Laboratory work supports a role. In human pancreatic islets (clusters of insulin-making cells), Tirzepatide’s insulin release fell when either receptor was blocked. In mice lacking the GLP-1 receptor, Tirzepatide still made the body more responsive to insulin.

Fat cells lack working GLP-1 receptors, so among Wegovy, Ozempic and Mounjaro, only Mounjaro can act on them directly. GIP helps white fat soak up fat after meals and makes fat tissue more responsive to insulin. That may keep fat out of organs where it does harm. Yet GIP’s relationship with fat cuts both ways. GIP favours fat storage, and its levels run higher in people with obesity. How these effects combine in the living body is not yet established.

Human evidence is thinner on appetite. Tirzepatide substantially reduces appetite and food intake. However, short-term GIP infusions in people with overweight or obesity did not change hunger, fullness or how much they ate.

Nausea is a second possible role. In mice, rats and shrews, a GIP-activating drug eased the nausea triggered by GLP-1 drugs. It worked partly through nerve cells in the hindbrain, at the base of the brain. Only one human study has tested this, finding a modest benefit when combined with liraglutide. Besides, trial tools for measuring stomach and gut side effects are relatively insensitive.

Switching the GIP receptor on and blocking it both reduce weight when combined with GLP-1 action. In monkeys, a GIP-blocking antibody alone cut weight by 2%. Paired with a GLP-1 drug, it produced 15% weight loss, against 9% for the GLP-1 drug alone.

An experimental medicine, Maridebart Cafraglutide, blocks the GIP receptor while activating GLP-1, and is now in advanced trials. Scientists call this contradiction the GIP receptor paradox. Three main explanations are under investigation, and none is settled:

Switched On Until It Switches Off: Constant stimulation may desensitise the GIP receptor (make it less responsive), so long-term activation ends up mimicking a block. In obese mice, a long-acting GIP activator and a GIP-blocking antibody produced almost identical weight loss. However, bone still responded to long-term activation, and there is no evidence yet of desensitisation in brain appetite centres.

Two Routes to the Same Place: Activation and blocking may work through different brain circuits or cell signalling pathways that end in the same result. They may also leave GLP-1 receptors working at different levels. All of these ideas remain under investigation.

Mostly a Powerful GLP-1 Medicine: Some experts argue Tirzepatide works mainly through GLP-1, with GIP contributing little. In addition, it may activate the GLP-1 receptor in a “biased” way, favouring some cell signals over others. This view sits uneasily with Tirzepatide’s stronger grip on the GIP receptor and its larger effects than GLP-1-only drugs.

Short-term human studies pairing Tirzepatide with single-receptor blockers should help settle the question. The heart raised a separate concern. Laboratory and genetic studies suggested GIP could help or harm the heart, while human population studies found no clear effect. In mice, a long-acting GIP activator enlarged heart-attack scars.

A trial of more than 13,000 people with type 2 diabetes and heart disease offered reassurance. Over about four years, Tirzepatide prevented major heart events at least as well as dulaglutide, a heart-protective GLP-1 drug. It also reduced all-cause mortality and kidney disease progression. How GIP might contribute to kidney benefits remains unclear, since no evidence shows GIP receptors in the kidney.

Why the Licence Matters More Than the Brand Name

In the Ozempic patient leaflet, weight loss appears in one place: a list of common side effects. It sits between tiredness and less appetite, among effects reaching up to 1 in 10 people. Wegovy’s leaflet, for the same molecule, opens by describing a medicine for weight loss and weight maintenance. It explains that the drug acts on brain receptors controlling appetite. Mounjaro’s leaflet covers both type 2 diabetes and weight loss in a single document.

The licence explains the gap. It sets out the conditions and doses a medicine is approved for; prescribing outside them is off-label. Licences can also widen over time. After a large heart trial, the UK regulator widened the Semaglutide 2.4 mg licence.

The Medicines and Healthcare products Regulatory Agency approved it to reduce the risk of heart attack and stroke. It covers adults with established heart or circulatory disease and a body mass index (BMI) of 27 or more. In the US, Tirzepatide is licensed for obstructive sleep apnoea, where breathing repeatedly stops during sleep. Semaglutide 2.4 mg is licensed there for a serious form of fatty liver disease. On paper, the licence decides what Wegovy, Ozempic, and Mounjaro are for. In practice, a longer chain decides who actually receives them on the NHS:

The Licence Sets the Limits: A licence makes a medicine legal to prescribe for its approved uses and doses. It does not bring NHS funding. For weight management, the licence specifies who qualifies, through BMI thresholds and weight-related health problems.

The Appraisal Decides Who the NHS Treats: The National Institute for Health and Care Excellence (NICE) reviews each medicine’s evidence and cost through a technology appraisal. Its 2023 appraisal limited NHS Semaglutide to people with a BMI over 35 and a weight-related condition. Treatment was capped at two years and confined to specialist services. Its 2024 appraisal of Tirzepatide kept the same eligibility, dropped the two-year limit and allowed wider settings, including primary care. For some groups, NICE defines obesity from a lower BMI of 27.5. These include people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family background. Their heart and metabolic risks rise at a lower BMI.

Local Boards Fund the Service: Integrated care boards, the regional NHS bodies holding local budgets, must provide NICE-approved treatments within three months. They were therefore obliged to offer Semaglutide for obesity by June 2023. Eighteen months after approval, though, 7 of 41 responding boards did not fund it. Only 66% funded both the medicine and the services needed to prescribe it. Some limited it to people with life-threatening obesity or those awaiting weight loss surgery.

A Specialist Service Prescribes: Between September 2023 and April 2024, specialist services prescribed Wegovy to 838 patients across 40 boards. NICE had projected 13,500 people on the drug by the end of March 2024. In 2024, 49,690 people were waiting for specialist weight services, with a median wait of 7.9 months (half waited longer). Five boards commissioned no specialist service at all.

For Wegovy, Ozempic and Mounjaro, the route to an NHS prescription now differs by medicine and by purpose. Tirzepatide’s wider route soon hit cost barriers. Implementing NICE’s criteria would have exceeded the NHS budget impact test, a spending check for new treatments. NHS England therefore secured a funding variation, allowing a phased rollout.

At first, eligibility requires a BMI over 40 plus at least four of five weight-related conditions. They are high blood pressure, abnormal blood fats, obstructive sleep apnoea, heart disease from narrowed arteries and type 2 diabetes.

Specialist societies have proposed phasing Semaglutide similarly, starting with the most time-critical needs. Some urgent needs fall outside NICE’s criteria altogether. Examples include weight loss required before organ transplant, cancer surgery or fertility treatment. These may be best managed in hospital, alongside the teams who need the weight loss.

The two-year cap on Semaglutide has drawn criticism, because obesity is a chronic disease that tends to return. GLP-1 treatment for diabetes, by contrast, carries no stopping rule. Yet NICE’s type 2 diabetes guideline keeps GLP-1 medicines as a fourth-line option, after three other treatments. The guideline recommends stopping them after six months without meaningful falls in HbA1c and weight.

How Wegovy, Ozempic and Mounjaro Compare in Trials and Everyday Life

Separate trials have reported weight reductions of up to 22.9% with Tirzepatide, after nearly three and a half years. Semaglutide’s equivalent figure was 16.7%, after nearly two years. Yet figures from separate trials cannot settle how Wegovy, Ozempic and Mounjaro compare. People, timescales, and designs all differ, so a direct randomised trial was needed. In a randomised trial, chance decides who receives which treatment.

That trial ran at 32 sites in the US and Puerto Rico between April 2023 and November 2024. It enrolled 751 adults living with obesity, or with overweight plus a related health problem, but without type 2 diabetes.

Participants averaged 113 kg and had lived with obesity for an average of 16 years. Around one in five were Black, and one in four Hispanic or Latino. Each person took Tirzepatide or Semaglutide at the highest weekly dose they could tolerate for 72 weeks. About nine in ten reached the top dose of their medicine. Alongside the medicine, everyone received advice on nutrition and physical activity.

After 72 weeks, average weight loss was 20.2% with Tirzepatide and 13.7% with Semaglutide. In kilograms, that meant 22.8 kg against 15.0 kg. Losing at least a quarter of body weight was about twice as likely on Tirzepatide (31.6% vs 16.1%). Almost one in five people on Tirzepatide lost 30% or more, against fewer than one in ten on Semaglutide. Tirzepatide further reduced waist size by 5.4 cm. In both groups, women lost about 6 percentage points more weight than men.

Side effects were similar overall, reported by 76.7% of people on Tirzepatide and 79.0% on Semaglutide. Vomiting was less common on Tirzepatide, at 15.0% against 21.3%. Fewer people stopped Tirzepatide because of side effects: 6.1% against 8.0%. Injection-site reactions, however, were more common with Tirzepatide, at 8.6% against 0.3%.

Eli Lilly, which makes Tirzepatide, funded and helped design the trial. Seven of the eleven authors were affiliated with the company. The trial was open-label, so participants knew which drug they were taking. Its results nonetheless match earlier blinded trials, where participants did not know their treatment.

A later analysis, designed after the trial, examined predicted heart risk in 576 participants without heart disease. Their predicted 10-year risk averaged 9.3% at the start. It fell by 2.36 percentage points on Tirzepatide and 1.35 percentage points on Semaglutide. In relative terms, that is roughly 13% lower risk with Tirzepatide.

The gap appeared by week 12, before most weight had been lost. However, these figures come from risk equations, and no actual heart attacks or strokes were counted. No trial has yet compared real heart events between the two medicines.

Researchers have also compared the two medicines at diabetes doses. A 40-week trial in eight countries, including the UK, compared three Tirzepatide doses with Semaglutide 1 mg, the Ozempic dose. It involved 1,879 adults whose diabetes was not controlled by metformin, a standard diabetes tablet.

Weight fell by 7.6 kg, 9.3 kg, and 11.2 kg on Tirzepatide, compared with 5.7 kg on Semaglutide. Each Tirzepatide dose also further lowered HbA1c. However, stopping because of side effects was more common on Tirzepatide: 6.0% to 8.5% versus 4.1%. Higher Semaglutide doses were not available as comparators at the time, and Eli Lilly also funded this trial.

Taken together, trials give a guide to typical results. Tirzepatide 15 mg typically brings about 20% weight loss within a year, or about 15% with type 2 diabetes. Semaglutide 2.4 mg typically brings about 15%, or about 10% with diabetes. Most of that weight comes off within the first six months.

Outside trials, average weight loss is smaller. A US study of linked health records compared 18,386 adults starting Mounjaro or Ozempic between May 2022 and September 2023. Only about half had type 2 diabetes. Among people still taking their medicine, one-year weight loss was 15.3% on Mounjaro and 8.3% on Ozempic.

Within a year, 42.3% on Mounjaro lost at least 15%, against 18.1% on Ozempic. People without type 2 diabetes lost more weight than those with it on both drugs. More than half stopped treatment during the study, after an average of 165 days. After stopping, one-year weight loss shrank to 11.4% and 6.2%.

Shortages, side effects and cost may all affect how long people stay on Wegovy, Ozempic and Mounjaro. Moderate to severe stomach and gut problems occurred at similar rates on both drugs.

These everyday figures have their own caveats. The study used diabetes brands, with standard full doses of 0.5 mg for Ozempic and 5 mg for Mounjaro. People who were not losing weight may have been more likely to stop or switch. Moreover, health records capture weight only at appointments. On the other hand, the study included groups often excluded from trials, such as people with recent major depression. Patients came from 35 states and were not representative of the country as a whole.

What the Differences Between Wegovy, Ozempic and Mounjaro Mean for You

NICE’s 2025 obesity guideline asks professionals to agree on goals as ordinary as tying shoelaces or breathing easily on stairs. Other examples include clothes fitting better and playing actively with children or grandchildren. Professionals are also asked to address what drives a person’s weight, such as social context, mental health and stigma.

Seen through that lens, the differences between Wegovy, Ozempic and Mounjaro become practical questions. Behind each brand stand three facts:

1. The medicine inside
2. The dose
3. The licence

Canada’s 2025 obesity medication guideline lists what to weigh when choosing a medicine with a professional. These include likely benefits for existing health conditions, effects on weight, and possible side effects. Others are whether it is an injection or a pill, how often it is taken, interactions and cost. Treatment goals, the guideline adds, should focus on outcomes that matter to the individual.

For anyone comparing Wegovy, Ozempic and Mounjaro, NICE describes weight management as a long-term process needing ongoing support. In England, weight loss medicines are meant to come with that support. They are intended for services offering wraparound care, covering diet, physical activity and psychological wellbeing.

As Tirzepatide moves into primary care, that support will need significant investment. Using the medicines alone, without it, would be a new, untested and potentially harmful approach. Digital services may help, although the NHS-approved providers are intensive and may not meet demand in their current form.

NICE lists social prescribers, health coaches, pharmacists and NHS Talking Therapies (psychological therapy services) as sources of support. Local and online groups, healthcare-endorsed apps, and community walking or gardening groups also feature. These can be used while waiting for treatment and alongside it.

A person’s decision to decline a referral should be respected, with further chances offered at later appointments. Professionals should also respect a choice not to discuss weight, and use language and images that avoid stigma. They should avoid diagnostic overshadowing, which means blaming every symptom on weight. Someone arriving with hip pain, for example, should have that pain dealt with first.

Measurement is shifting too. NICE advises interpreting BMI with caution, because it does not directly measure fat around the middle. For adults with a BMI under 35, it also recommends measuring waist-to-height ratio. NICE classifies a ratio of 0.4 to 0.49 as healthy and 0.5 to 0.59 as increased risk. A ratio of 0.6 or more counts as high. NICE’s simple message is to keep the waist to less than half of height.

Canadian guidance adds the idea of a “best weight”, the weight a body settles at with healthy behaviours. That weight may not match an ideal BMI. Where more weight loss is needed for health, more intensive medicines or surgery can be considered.

Sources

• Albor C, Anyiam O, Boyle LD, Makaronidis J, et al. The Role of GLP1 Receptor Agonists and Multi-agonist Incretin Therapies for Specific Obesity-related Health Conditions: Evidence and Rationale for Prioritisation. Curr Obes Rep. 2026;15(1):29.
• Andreasen CR, Andersen A, Vilsbøll T. The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease. Diabetologia. 2023;66(10):1846–1858.
• Ansari S, Mazaheri T, O’Donnell K, Waite M, Cann A, Abdel-Malek M, Boyle L, Tweedlie L, Scholtz S, Hameed S, Izzi-Engbeaya C, Chahal H, Tan T. Time to unshackle the medical treatment of obesity in the NHS. Clin Med (Lond). 2024 May;24(3):100206.
• Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, Das S, Lee CJ, Glass LC, Senyucel C, Dunn JP. Tirzepatide as compared with Semaglutide for the treatment of obesity. N Engl J Med 2025;393:26–36.
• Bergmann NC, Lund A, Gasbjerg LS, et al. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. Diabetologia 2019;62:665–675
• Borner T, Geisler CE, Fortin SM, et al. GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis in preclinical models. Diabetes 2021;70:2545–2553
• Campbell JE, Drucker DJ. Therapeutic targeting of the GIP receptor—revisiting the controversies. Diabetes 2025;74:1320–1325
• Campos-Rivera PA, Alfaro-Ponce B, Ramírez-Pérez M, Bernal-Serrano D, Contreras-Loya D, Wirtz VJ (2025) Quality of information and social norms in Spanish-speaking TikTok videos as levers of commercial practices: The case of Semaglutide. Soc Sci Med 366:117646.
• Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab 2018; 18: 3-14.
• Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–2786.
• Davies M, Færch L, Jeppesen OK, et al.; STEP 2 Study Group. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021;397:971–84.
• de Bray A, Schnitzer H, Mahase E, Singh P, Andrews R, McGowan BM, Le Brocq S, Wilding JPH, Flint SW, Hazlehurst JM. Variation in the Commissioning of Semaglutide for the Treatment of Obesity and Overweight Across England: Results of Three Freedom of Information-Based Mapping Exercises Across the 42 Integrated Care Boards of England. Clin Obes. 2026 Feb;16(1):e70044.
• Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, for subcutaneous use: Highlights of Prescribing Information and Full Prescribing Information (US). Label revised 4/2026.
• Eli Lilly Nederland B.V. Mounjaro (tirzepatide) KwikPen 2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg pre-filled pen: Package leaflet: Information for the patient. emc (electronic medicines compendium). Leaflet last revised April 2026.
• European Medicines Agency. Shortage of Ozempic. October 19, 2022.
• Fisher M. Guidelines on the Management of Type 2 Diabetes. J. Diabetes Endocr. Pract. 2022;5:135–137.
• Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503–515.
• Gasbjerg LS, Helsted MM, Hartmann B, et al. Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals. Diabetes 2019;68:906–917
• Ibrahim ARN, Orayj KM. Impact of ADA Guidelines and Medication Shortage on GLP-1 Receptor Agonists Prescribing Trends in the UK: A Time-Series Analysis with Country-Specific Insights. J Clin Med. 2024 Oct 20;13(20):6256.
• Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med 2025; 392:958-71.
• Mailhac A, Pedersen L, Pottegård A, Søndergaard J, Mogensen T, Sørensen HT, Thomsen RW. Semaglutide (Ozempic®) Use in Denmark 2018 Through 2023 ‒ User Trends and off-Label Prescribing for Weight Loss. Clin Epidemiol. 2024 Apr 25;16:307-318.
• Mamas MA, Bays H, Li R, Upadhyay N, Irani T, Senyucel C, Dunn JP, Liu-Seifert H. Tirzepatide compared with Semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial. Eur Heart J Open. 2025 Sep 2;5(5):oeaf117.
• Mulvihill C, Parretti HM, Aswani N, on behalf of the Guideline Committee. Overweight and obesity management: summary of updated NICE guidance. BMJ. 2025;391:r2286.
• National Institute for Health and Care Excellence. Overweight and obesity management (NICE guideline NG246). 2025.
• NHS-England, 2025. Interim commissioning guidance: Implementation of the NICE Technology Appraisal TA1026 and the NICE funding variation for tirzepatide (Mounjaro®) for the management of obesity.
• NICE, “Semaglutide for Managing Overweight and Obesity NICE TA875,” 2023.
• NICE, “Tirzepatide for Managing Overweight and Obesity NICE TA1026,” 2024.
• Nicholls SJ, Pavo I, Bhatt DL, et al.; SURPASS-CVOT Investigators. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med 2025;393:2409–2420
• Novo Nordisk A/S. Ozempic (Semaglutide) 0.5 mg solution for injection in pre-filled pen: Package leaflet: Information for the patient. emc (electronic medicines compendium). Leaflet last revised 11/2025.
• Novo Nordisk A/S. Rybelsus (oral Semaglutide) 1.5 mg tablets: Summary of Product Characteristics. emc (electronic medicines compendium). Date of revision of text 03/2026.
• Novo Nordisk A/S. Wegovy (Semaglutide) FlexTouch 0.25 / 0.5 / 1 / 1.7 / 2.4 mg pre-filled pen: Package leaflet: Information for the patient. emc (electronic medicines compendium). Leaflet last revised 06/2026.
• Novo Nordisk A/S. Ozempic (Semaglutide) 0.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. emc (electronic medicines compendium). Date of revision of text 07/2026.
• Novo Nordisk A/S. Wegovy (Semaglutide) 2.4 mg FlexTouch solution for injection in pre-filled pen: Summary of Product Characteristics. emc (electronic medicines compendium). Date of revision of text 07/2026.
• Overgaard R. V., Birkhan O., Rathor N., et al., “Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach,” Diabetes, Obesity and Metabolism 28, no. 7 (2026): 5982–5991.
• Pedersen SD, Manjoo P, Dash S, Jain A, Pearce N, Poddar M. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update. CMAJ. 2025 Aug 10;197(27):E797-E809.
• Plotkin M, Ivkovic M, Smith I, Rathor N, Chowdhury R, Hodkinson A, Kushner RF. Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes. Diabetes Obes Metab. 2026 Aug;28(8):7237-7246.
• Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 2018; 6: 275-86.
• Propfe LE, Seifert R. Misrepresentation of Semaglutide in social media. Naunyn Schmiedebergs Arch Pharmacol. 2026 Jan;399(1):815-832.
• Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Brar R, Baker C, Gluckman TJ, Stucky NL. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024 Sep 1;184(9):1056-1064.
• Ruiz PL, Karlstad Ø, Nøkleby K, et al. Pharmacological treatment of obesity in adults in Norway 2004-2022. Diabetes Obes Metab. 2024.
• Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab 2020; 31: 410-21.
• Santulli G. From needles to pills: oral GLP-1 therapy enters the obesity arena. Cardiovasc Diabetol Endocrinol Rep. 2025 Oct 6;11(1):31.
• Stallion C, Khan T, Guerrero C, Tsipas S, Wozniak G. Social Media Discussions of Anti-Diabetic Drugs and the Popularity of GLP-1 Therapies: Content Analysis. JMIR Diabetes. 2026 Aug 26;11:e87590.
• Tsipas S, Khan T, Loustalot F, Myftari K, Wozniak G. Spending on glucagon-like peptide-1 receptor agonists among US adults. JAMA Netw Open. 2025;8(4):e252964.
• Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, Adamo K, Alberga A, Bell R, Boulé N, Boyling E, Brown J, Calam B, Clarke C, Crowshoe L, Divalentino D, Forhan M, Freedhoff Y, Gagner M, Glazer S, Grand C, Green M, Hahn M, Hawa R, Henderson R, Hong D, Hung P, Janssen I, Jacklin K, Johnson-Stoklossa C, Kemp A, Kirk S, Kuk J, Langlois MF, Lear S, McInnes A, Macklin D, Naji L, Manjoo P, Morin MP, Nerenberg K, Patton I, Pedersen S, Pereira L, Piccinini-Vallis H, Poddar M, Poirier P, Prud’homme D, Salas XR, Rueda-Clausen C, Russell-Mayhew S, Shiau J, Sherifali D, Sievenpiper J, Sockalingam S, Taylor V, Toth E, Twells L, Tytus R, Walji S, Walker L, Wicklum S. Obesity in adults: a clinical practice guideline. CMAJ. 2020 Aug 4;192(31):E875-E891.
• Wharton S, Lingvay I, Bogdanski P, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025;393(11):1077–1087.
• Whitley HP, Trujillo JM, Neumiller JJ. Special report: potential strategies for addressing GLP-1 and dual GLP-1/GIP receptor agonist shortages. Clin Diabetes. 2023;41(3):467-473.
• Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, Capozzi ME, van der Velden WJ, Stutsman C, Cardona GR, et al.2020Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 5e140532.